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Cell motility is stimulated by extracellular stimuli and initiated by intracellular signaling proteins that localize to sites of cell contact with
the extracellular matrix termed focal contacts. Focal adhesion kinase (FAK) is an intracellular protein-tyrosine kinase (PTK) that acts to
regulate the cycle of focal contact formation and disassembly required for efficient cell movement. FAK is activated by a variety of cell
surface receptors and transmits signals to a range of targets. Thus, FAK acts as an integrator of cell motility-associated signaling events. We
will review the stimulatory and regulatory mechanisms of FAK activation, the different signaling connections of FAK that are mediated by a
growing number of FAK-interacting proteins, and the modulation of FAK function by tyrosine and serine phosphorylation. We will also
summarize findings with regard to FAK function in vertebrate and invertebrate development as well as recent insights into the mechanistic
role(s) of FAK in promoting cell migration. As increased FAK expression and tyrosine phosphorylation have been correlated with the
progression to an invasive cell phenotype, there is growing interest in elucidating the important FAK-related signaling connections promoting
invasive tumor cell movement. To this end, we will discuss the effects of FAK inhibition via the dominant-negative expression of the FAK C-
terminal domain termed FAK-related non-kinase (FRNK) and how these studies have uncovered a distinct role for FAK in promoting cell
invasion that may differ from its role in promoting cell motility.
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The integrin family of transmembrane receptors link the
extracellular matrix (ECM) to the intracellular actin cyto-
skeleton at points of cell–substrate interaction termed focal
contacts [1]. In addition to this structural role, integrin
clustering can initiate intracellular signaling events that
are important for cell growth, survival, and migration.
One type of signaling event stimulated by integrins is the
tyrosine phosphorylation of cytoskeletal as well as signaling
proteins. However, since integrins do not possess catalytic
activity, the signals initiated by ECM–integrin interactions
must be transduced into cells through the activation of
integrin-associated proteins [2–4]. A number of different
intracellular protein-tyrosine kinases (PTKs) such as Abl,
Syk, focal adhesion kinase (FAK), and Src-family PTKs are
activated by integrin clustering or cell binding to ECM
proteins. Since integrins are comprised of various alpha and
beta subunits and each can facilitate distinct signaling
events [5], it is important to remember that the activation
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within cells.
As recent reviews have covered topics such as the first 10
years of FAK studies [6], biochemical signals elicited by
FAK activation [7,8], FAK signaling in the control of cell
survival and cell cycle progression [9,10], the role of FAK
in the nervous system [11], and the connections of increased
FAK expression to cancer [12–14], this review will focus
on how FAK is linked to multiple intracellular signaling
pathways controlling cell motility and invasion. To this end,
we will make reference to an earlier review [15] for many
citations prior to 1999 as we put emphasis on the FAK-
related studies published in the last 4 years.
1.1. Structural features of FAK
FAK is a cytoplasmic PTK that localizes to focal contacts
and adhesions as its name implies. Despite early studies
supporting the idea of direct binding of h-integrins to the
FAK N-terminal domain [6,8], FAK is localized to sites of
integrin clustering at focal adhesions through indirect pro-
tein–protein interactions of the C-terminal focal adhesion
targeting (FAT) region in FAK (Fig. 1). This FAK FAT
region contains binding sites for integrin-associated proteins
such as paxillin and talin [16,17]. The FAK C-terminal
region also contains two proline-rich motifs that serve as
binding sites for a variety of Src homology 3 (SH3) domain-
containing proteins including the p130Cas adaptor protein
[18], the Graf Rho-GTPase activating protein (GAP), and
the ASAP1 Arf-GAP [6] (Fig. 2). As will be discussed later
in this review (Section 4), a protein product encompassing
the FAK C-terminal domain termed FAK-related non-kinase
(FRNK) is selectively expressed in chicken embryo cells
and within vascular smooth muscle cells (VSMC) during
mouse development [19,20]. Exogenous FRNK expression
functions as a dominant-negative inhibitor of FAK functionFig. 1. FAK structural features and alternate splice forms. FAK is composed of a N
amino acid FAT region within the C-terminal domain. FAK also contains three p
domain docking sites. The major FAK phosphorylation site is at Tyr-397. Altern
surrounding FAK Tyr-397. The box numbers correspond to amino acid residues
termed FRNK is also expressed as a separate mRNA transcript, is identical to resi
FAK signaling.in many cell types and it has been hypothesized to function
as a competitive inhibitor of FAK targeting to integrins and
focal contact sites.
The FAK N-terminal region harbors a FERM (band
four point one, ezrin, radixin, and moesin) homology
domain followed by a proline-rich motif that has been
identified as a SH3 binding site for Src-family PTKs. The
central kinase region of FAK is highly conserved from
humans down to Drosophila and C. elegans [8]. When
activated, the FAK catalytic domain facilitates autophos-
phorylation of Tyr-397. In brain tissues and neuronal
cells, alternatively spliced isoforms of FAK have been
identified that contain 6–28 amino acid insertions sur-
rounding Tyr-397 termed FAK box 6, box 7, and box 28,
respectively [11] (Fig. 1). In the analysis of the murine
FAK genomic sequence on chromosome 15 (NCBI, Build
32), FAK box 6, box 7, and box 28 have been identified
as exons 15, 17, and 14, respectively. Importantly, the
protein products of alternatively spliced FAK exhibit
elevated levels of tyrosine phosphorylation in cells and
higher levels of associated kinase activity in vitro com-
pared to wild-type FAK [21]. As discussed in detail
below, it has been proposed that the elevated activity
of alternately spliced FAK isoforms may result from the
conformational activation of FAK leading to a state of
intramolecular phosphorylation of FAK Tyr-397 as op-
posed to an intermolecular-mediated mechanism of FAK
phosphorylation through integrin-initiated clustering [22].
1.2. Mechanisms of FAK activation
In many cell types, FAK activation leads to the Src
homology 2 (SH2) domain-mediated binding of Src-
family PTKs to the motif surrounding the FAK Tyr-397
phosphorylation site. Src binding to FAK promotes in-
creased Src kinase activity and in turn, Src-mediated-terminal FERM homology domain, a central kinase domain, and a f 150
roline-rich (Pro-1 through 3) regions that serve as Src-homology 3 (SH3)
ate-spliced FAK isoforms (box 6, 7, and 28) contain amino acid insertions
added and the insertion sequences are listed. The FAK C-terminal domain
dues 668–1052 of FAK, and FRNK functions as a competitive inhibitor of
Fig. 2. Binding sites for FAK-associated proteins. The N-terminal FAK FERM domain is important for signal integration from growth factor receptors such as
the Eph-family, EGF and PDGF receptor PTKs as well as the cytoplasmic Etk PTK. The FERM domain interacts also with a scaffolding protein of the JNK
kinase pathway (JSAP1), the cytoskeletal-associated protein ezrin, and can associate with SUMO proteins. The FAK C-terminal FAT domain binds cytoskeletal
proteins paxillin and talin and mediates FAK localization to integrin-enriched focal adhesions. The FAT domain also makes direct contacts to p190RhoGEF to
facilitate Rho-GTPase activation. SH3 containing proteins such as Trio and c-Src bind to the FAK Pro-1 region, whereas other SH3-containing proteins such as
p130Cas, Graf, and ASAP1 can bind to FAK C-terminal Pro-2 and Pro-3 motifs. Phosphorylation of FAK at Tyr-397 creates high-affinity SH2 binding sites for
Src-family PTKs and the Shc adaptor protein, whereas Tyr-925 phosphorylation promotes the SH2-mediated binding of the Grb2 adaptor protein. FAK
phosphorylation within the kinase domain activation loop at Tyr-576 and Tyr-577 promotes maximal catalytic activity. Inhibition of FAK catalytic activity is
associated with FIP200 binding to the FAK kinase domain and SOCS protein binding regulated by FAK Tyr-397 phosphorylation. FAK phosphorylation at Tyr-
861 may alter integrin binding and FAK phosphorylation at Ser-910 by either protein kinase C or ERK2 may negatively affect paxillin binding to the FAK FAT
domain.
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vation loop at Tyr-576 and Tyr-577 is needed for
maximal FAK-associated activity [23]. Src activity in
complex with FAK promotes the phosphorylation of
FAK C-terminal domain residues Tyr-861 and Tyr-925,
the latter becoming a binding site for Grb2 adaptor
protein SH2 domain [15] (Fig. 2). It is the dual FAK–
Src PTK complex that promotes the tyrosine phosphory-
lation of adaptor proteins such as Shc, paxillin, and
p130Cas as well as cytoskeletal proteins such as a-
actinin [24]. Many of these tyrosine phosphorylation
events initiated by FAK–Src PTK complex can lead to
the activation of multiple intracellular signaling cascades
[8,9,15]. However, despite the knowledge gained in
identifying FAK phosphorylation sites, targets, and asso-
ciated signaling events, the precise mechanism of FAK
activation remains elusive. This is likely due to the fact
that FAK can be activated by multiple inputs and in
different manners.
1.3. Intermolecular FAK phosphorylation
It is widely accepted that clustering of integrins or chime-
ric molecules containing the cytoplasmic domains of integ-
rins can promote FAK activation and an intermolecular model
of dimerization-mediated FAK activation has been supported
by studies with gyrase B [22] or leucine zipper [25] fusions
with FAK. Additionally, analyses of various FAK mutantshave revealed that targeting of FAK to focal contacts is
important in the regulation of its activity [26]. As FAK is
targeted to focal contact through its interaction with integrin-
associated proteins, paxillin-null fibroblasts exhibit reduced
fibronectin (FN)-stimulated FAK activation [27] and muta-
tions of FAK within the FAT domain that disrupt paxillin
binding exhibit reduced integrin-stimulated phosphorylation
in cells [28,29]. However, analyses of talin-null cells revealed
that both FAK and Src PTK activities were equally stimulated
by FN compared to normal fibroblasts [30], and various h-
integrin mutants have been used to show that FAK localiza-
tion to focal contacts is separable from integrin-mediated
FAK activation [31]. Thus, there may exist a hierarchy of
FAK FAT domain-interacting proteins needed for integrin-
stimulated FAK activation. Additionally, as the tools to
evaluate FAK activation now include a number of different
site- and phospho-specific antibodies, integrin clustering and
cell plating on FN experiments are yielding new insights into
the complex nature of FAK activation. Notably, clustering of
a5h1 on suspended cells yielded increased FAK phosphor-
ylation at Tyr-861, whereas cell spreading on immobilized
a5h1 ligands promoted FAK phosphorylation at both Tyr-
397 and Tyr-861 [32]. As the C-terminal Tyr-861 site in FAK
is readily transphosphorylated by Src-family PTKs [10], and
Src-family PTKs have been shown to be differentially acti-
vated by integrin clustering [33] and by direct interactionwith
particular h-integrin cytoplasmic domains [34], the processes
of FAK activation clearly involves the phosphorylation of
Fig. 3. Models of FAK activation states associated with integrin-enriched
focal contacts. (A) In quiescent and adherent cells, FAK localizes to
vinculin-enriched focal contacts through association with integrin-associ-
ated proteins paxillin and talin. FAK can be phosphorylated at Tyr-397, yet
exhibit low levels of in vitro kinase activity due to conformational
constraints limiting catalytic activity and c-Src SH2 binding to the FAK
Tyr-397 site. (B) Cell spreading on matrix proteins promotes integrin
clustering and FAK activation through both intermolecular clustering and
intramolecular release of conformational restraints. Maximal autophosphor-
ylation at FAK Tyr-397 promotes the SH2-mediated recruitment of Src-
family PTKs, phosphorylation of FAK Tyr-576/577 within the kinase
domain activation loop, and the formation of a FAK–Src PTK signaling
complex.
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findings that kinase-inactive FAK can become trans-phos-
phorylated when expressed in FAK-null cells [35].
1.4. Intramolecular activation of FAK
Intramolecular constraints also play a role in regulating
FAK activity as FAK Tyr-861 phosphorylation has been
correlated with the enhanced cis- and trans-phosphoryla-
tion of FAK at Tyr-397 [36]. Deletions of the FAK N-
terminal domain result in constructs possessing higher
levels of activity in vitro and in vivo [15,22]. As
expression of the FAK FERM domain as an exogenous
construct can act in trans to inhibit FAK phosphorylation
in cells and the FAK FERM domain weakly binds to the
FAK kinase domain in vitro, it has been suggested that it
may function as an intramolecular inhibitor of FAK
activity [37]. Interestingly, ezrin has been identified as
a FAK FERM domain-interacting protein and ezrin over-
expression can promote FAK Tyr-397 autophosphoryla-
tion in an integrin- and Src PTK-independent manner
[38]. Similarly, the SH3-mediated binding of Trio to the
proline-rich motif following the FERM domain also
promotes increases in FAK-associated kinase activity
[39]. The idea that the FERM domain acts in a negative
fashion to limit FAK kinase activity is further supported
by findings that the FAK FERM domain interacts with
protein inhibitor of activated STAT1 (PIAS1), which
functions as small ubiquitin-like modifier (SUMO) ligase
[40]. SUMOylation of FAK occurred at Lys-152 within
the FERM domain and was associated with increased
FAK phosphorylation at Tyr-397 in an integrin-indepen-
dent fashion.
Taken together, evidence is accumulating that either post-
translational modification or target protein interactions with
the FAK FERM domain act to ‘‘release’’ a potential allo-
steric or conformational restraint limiting FAK catalytic
activity (Fig. 3). As the crystal structure of the ATP-bound
FAK kinase domain revealed that the activation loop region
was disordered [41], it is likely that conformational changes
within the FAK kinase domain are needed for maximal
activity. These secondary conformational changes required
for FAK activation have also tempered the success of using
mutagenesis within the FAK kinase domain to create con-
stitutively active mutants. ‘‘Super-FAK’’ was created by
glutamic acid replacement for lysine at FAK residues 578
and 581 in the activation loop that resulted in increased in
vitro kinase activity and paxillin tyrosine phosphorylation in
vivo [42]. However, Super-FAK overexpression only weak-
ly increased cell motility as a biological assay for increased
FAK signaling compared to wild-type FAK overexpression.
Finally, the regulation of FAK activity is also modulated
by proteins such as FAK-inhibiroty protein 200 kDA
(FIP200) that bind to the FAK kinase domain [43] and by
interactions with suppressor of cytokine signaling (SOCS)
proteins that target FAK for poly-ubiquitination and degra-dation [44]. FAK is also negatively regulated by the actions
of protein-tyrosine phosphatases (PTPs) such as SH2-con-
taining tyrosine phosphatase 2 (SHP2) [45,46] and low
molecular weight tyrosine phosphatase (LMW-PTP) [47].
Interestingly, cells lacking PTPa exhibit reduced FAK
tyrosine phosphorylation after integrin stimulation suggest-
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activation [48]. As treating normal fibroblasts with a phar-
macological inhibitor to Src PTKs recapitulated the PTPa-
null phenotype, it is likely that FAK is not a direct target of
PTPa. Instead, it is proposed that PTPa functions as an
integrin-stimulated Src PTK activator through the dephos-
phorylation of the regulatory C-terminal Tyr site in c-Src
[48]. This conclusion is consistent with the potential inter-
molecular activation of FAK by Src via Src-mediated trans-
phosphorylation of Tyr-397. To this end, c-Src can be
directly activated by binding and clustering of particular
h-integrin cytoplasmic tails such as the h3-integrin [34]. It
is for this reason that analyses of FAK Tyr-397 phosphor-
ylation may not always reflect FAK catalytic activation as
an autophosphorylation event. Therefore, one of the best
descriptions or models of FAK function remains as ‘‘an
activatable scaffolding protein’’ [4]; where the stimulated
nucleation of signaling proteins bound to FAK can be
initiated either through intrinsic autophosphorylation at
Tyr-397 or through transphosphorylation of this site.
1.5. FAK function modulated by phosphorylation
Src SH2-mediated binding to FAK Tyr-397 leads to the
generation of an activated Src-FAK signaling complex
[15]. Src facilitates maximal FAK activation through
phosphorylation at Tyr-576 and Tyr-577 within the FAK
kinase domain and Src phosphorylates additional sites
within the FAK C-terminal domain at Tyr-861 and Tyr-Fig. 4. FAK integrates inputs from a variety of cell surface-associated receptors.
activation as measured by increased tyrosine phosphorylation at Tyr-576, Tyr-5
activation via autophosphorylation at Tyr-397 or FAK can also function as a subst
FAK Tyr-397 phosphorylation may not always reflect an autophosphorylation eve925, the latter serving as a Grb2 SH2 binding site (Fig. 4).
Plasma membrane targeting of FAK constructs result in
elevated FAK Tyr-925 phosphorylation [49] and can pro-
mote adhesion-independent signaling to targets such as
ERK2/mitogen-activated protein kinase (MAP kinase)
[50]. However, membrane-targeted FAK constructs were
also selectively excluded from focal contact sites where
endogenous FAK was localized [49]. As Phe-925 mem-
brane-targeted FAK localized to focal contacts, it was
proposed that either phosphorylation at Tyr-925 or Grb2
SH2 binding to this site leads to the dissociation of FAK
from focal contacts [49].
Interestingly, the Tyr-925 site lies within the FAT domain
that is comprised of a four-helical bundle [51]. Tyr-925 lies
on the first turn following helix a1, with its side chain
accessible for phosphorylation. The surface grooves within
the FAK FAT domain serve as binding sites for paxillin.
Short peptide motifs in paxillin termed LD2 and LD4 that
assume amphipathic helical structures in solution [52]
mediate paxillin binding to the FAK FAT domain [16].
Notably, the Tyr-925 site is partially covered by one end
of the bound LD2 paxillin peptide, indicating that Grb2
binding to Tyr-925 and paxillin binding to FAT may be
mutually exclusive [52]. This supports the hypothesis that
an activated FAK signaling complex may dissociate from
focal contacts. To this end, Ser-910 is another site within the
FAK FAT domain that is phosphorylated during mitosis [53]
and after mitogen stimulation of cells [54]. Reduced binding
of paxillin has also been associated with FAK Ser-910Integrins, G protein linked, and growth factor receptors can facilitate FAK
77, Tyr-861, and Tyr-925. Motility-promoting stimuli can facilitate FAK
rate for other PTKs resulting in increased trans-phosphorylation of FAK. As
nt, FAK can be considered to function as a activatable scaffolding protein.
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a1 of the FAT domain, phosphorylation of Ser-910 may act
to globally alter the FAT domain helical bundle structure,
thereby weakening paxillin binding.
Other sites of FAK phosphorylation can also act to
modulate FAK localization within cells. Src-dependent
phosphorylation of FAK Tyr-861 is important in promoting
the association of FAK with an avh5 integrin signaling
complex after vascular endothelial growth factor (VEGF)
stimulation of endothelial cells [55]. As the Tyr-861 site lies
outside of the FAT domain, it remains to be determined how
this binding interaction is being mediated with the h5
integrin cytoplasmic tail. Nevertheless, the stimulated asso-
ciation of FAK with avh5 integrins is an important event in
the turnover of spent photoreceptor outer segment (OS)
fragments of retinal pigment epithelial (RPE) cells [56]. In
RPE cells, OS challenge stimulated FAK recruitment to the
apical surface, FAK association with avh5, and increased
FAK tyrosine phosphorylation at Tyr-397, Tyr-576, and Tyr-
861. FAK activity was required for the RPE-mediated
engulfment of OS fragments and transient FAK expression
in FAK-null fibroblasts was shown to facilitate OS fragment
internalization [56]. This proposed role of FAK in phago-
cytic signaling is similar to studies showing an important
role for FAK signaling in invasive Escherichia coli [57,58]
and Yersinia [59] uptake into mammalian cells.
Finally, during mouse brain development, cyclin-depen-
dent kinase 5 (Cdk5) promotes the phosphorylation of
FAK at Ser-732 in post-mitotic neurons [60]. Phospho-
S732-specific antibodies specifically stained ‘‘fork’’-like
microtubule (MT) structures near the cell nucleus and the
overexpression of a FAK Ala-732 mutant resulted in
disorganization of the microtubule fork, impaired nuclear
movement in cultured neurons, and altered neuronal posi-
tioning in vivo. As non-phosphorylated Ala-732 FAK accu-
mulated at centrosomes, similar to a phenotype observed in
Cdk5-deficient neurons, it was proposed that Cdk5-mediated
phosphorylation of FAK at Ser-732 promotes the organiza-
tion of a MT fork. This structure is proposed to play an
important role in pulling the nucleus into proximal neuronal
structures during neuronal outgrowth [60]. Additionally,
dynamic MTs are selectively stabilized during morphoge-
netic events such as cell migration and epithelial polarization
in addition to neuron outgrowth [61]. In particular, it has
been hypothesized that MTs might be part of a positive
feedback loop mechanism that maintains the stable polari-
zation of a directionally migrating cell [62]. Notably, integrin
signaling facilitates the stabilization of Mts and this has been
correlated with increased FAK tyrosine phosphorylation as
well as the activation of Rho-GTPase-mDia signaling [63].
Interestingly, studies with FAK-null fibroblasts showed that
FAK signaling was required for MT stabilization and that
activated mDia, but not active Rho, could bypass the
integrin-FAK requirement for MT stabilization [63]. As
integrin-stimulated and FAK-mediated MT stabilization
was correlated with the plasma membrane surface localiza-tion of the ganglioside GM1 lipid raft marker, it is possible
that FAK signaling directs MT polarization and stabilization
events in multiple cell types either directly through FAK Ser-
732 phosphorylation or indirectly through effects on lipid
cell surface expression.
1.6. FAK FERM domain-interacting proteins
As FAK connects to integrins through various C-terminal
domain-mediated interactions, FAK is also functionally
linked to various other proteins through N-terminal FERM
domain-mediated interactions. Structural analyses and se-
quence comparisons reveal that FERM domains are com-
prised of three lobes that contain multiple sites for both lipid
and protein binding [64]. Recent studies have begun to
identify FAK FERM targets and how these interactions may
affect FAK function. For instance, ezrin binding to the FAK
FERM domain can lead to integrin-independent FAK acti-
vation [38] and FAK FERM domain-mediated binding to
the Etk PTK has been proposed as a mechanism by which
Etk becomes activated by integrins [65]. The FAK FERM
domain also mediates the association with activated epider-
mal growth factor (EGF) and platelet-derived growth factor
(PDGF) receptor signaling complexes and this association
as well as FAK phosphorylation at Tyr-397 are important for
growth factor-stimulated cell motility [35]. Notably, full-
length kinase-inactive FAK or the exogenous FERM do-
main of FAK are readily transphosphorylated at Tyr-397 by
a component of the activated EGF receptor complex [35].
Although many FERM domains contain a motif similar to a
phosphotyrosine binding domain, FAK association with the
ephrin EphA2 receptor was constitutive with the inactive
and non-phosphorylated EphA2 receptor [66]. Whereas the
mode of FAK FERM and growth factor receptor interactions
remains to be determined, cell biological studies show that
this connection is important for EphA1-stimulated cell
adhesion, spreading, and cytoskeletal rearrangements [67].
Clearly, future structural studies of the FAK FERM domain
and the elucidation of how binding interactions are mediated
will yield important clues as to how FAK is connected to a
variety of different signaling pathways.2. Importance of FAK in developmental events
2.1. Mesodermal defects of FAK-null mice
Whereas the most reproducible activation of FAK occurs
when cells bind to and spread on ECM proteins, the first
insights into the functional role of FAK during these events
were derived from animal developmental studies. Null
mutation of fak in mouse embryonic stem (ES) cells by
homologous recombination resulted in death at embryonic
day (E) 8.5 [68]. Whereas normal and mutant embryos were
indistinguishable up to E7.0 (D. Ilic, unpublished observa-
tions), at E8.5, FAK-null embryos resembled the phenotype
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supports the conclusion that FAK plays an indispensable
role in events occurring in the period of E7.0 to E8.5 of
mouse development.
A major feature of mouse development at E7.0–8.5 is
the coordinated movement and subsequent differentiation of
mesodermal cells [69,70]. At this stage, mesodermal cells
form three cranio-caudal tissue columns; the paraxial me-
soderm that will envelop the neural tube and form somites,
the intermediate mesoderm involved in formation of the
urogenital system, and the lateral mesoderm that gives rise
to hemangioblasts which are precursors of endothelial cells.
FAK-null embryos exhibit an absence of somite formation, a
rudimentary non-beating heart or no heart at all, lack of
patent circulation, and a morphologically indistinguishable
notochord [68]. These mesodermal-derived defects suggest
that FAK expression is important for either the migration,
proliferation, differentiation, or survival of mesodermal cells
involved in embryo patterning.
2.2. FAK-null cells can undergo developmental differenti-
ation but not motility
Interestingly, hybridization of FAK-null embryos with
probes to either mox-1 or Brachyury, markers of somitoge-
netic mesoderm, revealed that they were expressed at E8.5,
suggesting that the embryos had the potential to form
notochord and somites [68]. Analyses of the in vitro
differentiation potential of FAK-null ES cells showed the
normal formation of cartilaginous nodules with associated
ossified areas and muscle fibers upon subcutaneous injec-
tion into nude mice [71]. Beating cardiac myocytes could
also be visualized in embryoid bodies generated from FAK-
null ES cells (D. Ilic, unpublished observations). Megakar-
yocytes, mast cells, neutrophils, and erythroblasts could be
derived from FAK-null ES cells in the presence of OP-9
stromal cells [71] and FAK-null mast cells have been
obtained from extended culture of non-adherent cells de-
rived from E8.5 embryos [72]. Whereas no apparent
markers of endothelial cells were present in FAK-null
embryos, endothelial cells could be derived from FAK-null
embryoid bodies in culture but not from E8.5 embryos [73].
Thus, in both in vitro and in vivo assays, it can be concluded
that FAK expression is not essential for mesodermal cell
differentiation.
In contrast to the lack of a role for FAK in differentiation,
mesodermal cells isolated directly from E7.5 FAK-null
embryos exhibited defective motility as observed by time-
lapse video microscopy [74]. It was determined that FAK-
null cells moved at approximately half the speed of wild-
type cells (42 versus 83 Am/h). As adherent cells isolated
directly from FAK-null embryos did not readily divide in
cell culture, a germline mutation in p53 was introduced into
the FAK-null background to enhance the proliferative ca-
pacity of adherent cells. Whereas mutation of p53 did not
affect the FAK-null embryonic lethal phenotype at E8.5,mesodermal cells isolated from E8.0 embryos exhibited
equal levels of proliferation in culture compared to wild-
type cells [74]. However, FAK-p53-null cells were more
rounded and poorly spread compared to wild-type cells.
Boyden chamber motility assays using FN revealed that
FAK-p53-null cells exhibited refractory responses and
formed an elevated number of focal contact sites as deter-
mined by interference reflection microscopy and vinculin
staining [74]. Importantly, after establishment of FAK-p53-
null fibroblasts in culture, these cells also moved at half the
speed as wild-type fibroblasts (0.36 versus 0.83 Am/min)
[75] and this difference was equivalent to the primary cells
isolated from FAK-null embryos.
It should be noted that mesodermal cell movement is not
the first migration-dependent event required in mouse
development [69,70]. During the early post-implantation
period at E4.5–5.0, primitive endoderm migrates from its
initial site to form an extra-embryonic parietal layer of
endoderm. These cells secrete collagen-, laminin-, and
dystroglycan-rich ECM layer termed the Reichert’s mem-
brane, an important protective structure at the maternal–
fetal interface that plays a role in subsequent stages of
trophoblast differentiation and placenta formation. Although
in vitro studies demonstrated that germline FAK deficiency
also impaired the migration potential of endodermal cells
[76], development proceeded normally in this compartment
of FAK-null embryos. One possibility to explain the appar-
ent discrepancy is that the distance to be covered by FAK-
null endodermal cells in early development may not be as
extensive as compared to mesodermal cell movement during
morphogenesis.
2.3. Role of FAK in trophoblast invasion
Rodent trophoblasts do not have to travel long distances
for invasion of the uterine wall in placenta formation. This
may explain why there was no overt placental phenotype in
FAK-null embryos even though one would expect it given
the role of FAK in cell migration. However, specialized
human placental epithelial cells, termed cytotrophoblasts,
have to traverse much larger distances during a tumor-like
process of invasion that anchors the conceptus to the uterus.
The ability of cytotrophoblasts to become invasive is part of
a tightly regulated, stepwise differentiation program [77].
Immunolocalization studies showed that FAK is expressed
at all stages of cytotrophoblast differentiation, whereas
staining with phospho-specific antibodies to phospho-Tyr-
397 FAK showed a specific localization in a subset of
invasive cytotrophoblasts near the uterine wall [78]. To
establish the importance of FAK in cytotrophoblast invasion
processes, an adenoviral-mediated strategy to deliver FAK
antisense mRNA was performed and resulted in the inhibi-
tion of ECM invasion compared to control virus-infected
cells [78]. Notably, cytotrophoblasts encounter similar
obstacles that metastatic tumor cells must overcome in order
to successfully invade surrounding tissues. The study of
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pothesis that FAK Tyr-397 phosphorylation may play a key
role in promoting the invasive phenotype of normal cyto-
trophoblasts and, by analogy, may also play an important
role in tumor progression.
2.4. FAK connections to an integrin signaling axis
One of the most reproducible means used to activate
FAK is the plating of cells onto an insoluble FN matrix [15].
Under these circumstances, the clustering of transmembrane
integrins such as a5h1 can promote increased FAK activity.
Interestingly, the timing and phenotype of the morpholog-
ical defects of FAK-null mice closely resemble the devel-
opmental defects of FN-null mice (Fig. 5) [68,79,80]. This
was an unexpected result. As FAK activation is associated
with a variety of integrin subunits, some of which do not
bind FN, and FAK can be activated by growth factor or G
protein-linked stimuli, a more severe phenotype associated
with the loss of FAK was anticipated. The developmental
results, however, strongly suggest that FN and FAK are
indispensable members of the same signaling pathway. This
signaling connection is of paramount importance at E7.5 to
E9.0 for the successful initiation and completion of gastru-
lation. Viewed from a developmental perspective, both FN-
and FAK-deficient mouse embryos had initiated gastrulation
and all three germ layers were present at E7.5, though
mutant embryos were smaller in size and exhibited a
concave amnion. At E8.5, the morphological defects were
more obvious and in both types of mutants, the abnormal-
ities could be grouped as: (A) deficit in mesenchyme; (B)
shortened anterior–posterior axis; (C) inability to form
somites; (D) morphologically non-distinct notochord; and
(E) cardiovascular defects.Fig. 5. Morphology of wild-type, FAK-null, and FN-null mouse embryos at
E8.5. Similar phenotypes of FAK- and FN-null mouse embryos suggest a
tight functional link between these two molecules. Both FAK- and FN-null
mutants have shortened anterior–posterior axis and lack somites. Headfold
structures are indicated by arrows.Whereas genetic background variances between FN-null
and FAK-null mice can contribute to differences in the
severity of phenotypes observed, the multiple similarities
in developmental defects support the hypothesis that these
molecules are functionally linked. In a classical outside–in
signaling paradigm, FN binding to integrins promotes FAK
activation and intracellular signaling. However, integrin
binding to FN can also facilitate the assembly of FN
molecules into a fibrillar matrix through inside–out signal-
ing [81]. As FN matrix architecture can influence cell
proliferation [82], this modulation of higher-order FN struc-
ture by integrins represents a bi-directional signaling axis
[83]. Interestingly, in E8.5 FAK-null embryos, FN matrix
organization appeared granular and less fibrillar than in
wild-type embryos [84]. This defect in FN matrix organi-
zation was also observed in cell culture as FAK localization
and activity at integrin-enriched focal contacts was required
for the generation of a fibrillar FN matrix. As the defective
FN matrix was attributed to impaired FN fibril assembly and
not alterations in either FN gene expression or secretion
[84], these results support the importance of a bi-directional
FN–FAK signaling axis intimately involved in both devel-
opmental and cell signaling events.
To this end, the targeted deletion of FAK expression
in the developing dorsal forebrain of mice also supports
the hypothesis that FAK functions in promoting basement
membrane assembly and/or remodeling [85]. Specific
deletion of FAK was accomplished by mating fak–flox
mice to mice expressing Cre recombinase under the
control of the endogenous emx1 promoter that becomes
active at E9.0 within neuroepithelial precursors of neu-
rons and glia [86]. The major phenotypic defects ob-
served were the abnormal organization of cortical
laminin-enriched basement membranes, over-migration of
neuronal cells in patches through the marginal zone,
altered dendritic branching, and reduced p130Cas tyrosine
phosphorylation in developing embryos [85]. Interesting-
ly, no detectable changes in either neuronal apoptosis or
proliferation were observed in the absence of FAK and
the generation of a neural-specific Cre line (nex-Cre)
revealed that the dendritic branching defect was a phe-
notype intrinsic to FAK-null neurons [85]. Staining for
laminin, collagen IV, and perlecan revealed altered orga-
nization and expression patterns at the outer surface of
the emx1 FAK-null cortex. The basement membrane and
neuronal positioning abnormalities were not intrinsic
defects of FAK-null neurons. Instead, in vitro expression
of Cre within emx1 FAK-null meningeal fibroblasts
resulted in the disruption of fibrillar-like laminin organi-
zation similar to the FN fibril assembly defects observed
with the growth of homozygous FAK-null fibroblasts in
culture [84]. Since emx1 promoter-driven Cre expression
was primarily in embryonic neurons and glia, it is likely
that the loss of FAK expression within glial cells con-
tributes to neuronal positioning and basement membrane
abnormalities in vivo.
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The strikingly similar cardiovascular developmental
defects observed in FN- and FAK-null embryos (as dis-
cussed above) further reinforce the importance of this
signaling axis. Antibody-mediated staining of wild-type
embryos revealed that FAK expression was equally distrib-
uted throughout many cell types and became particularly
abundant in developing vasculature [87]. Notably, embryos
lacking FN or FAK contain differentiated endothelial cells
or their precursors, but both fail to develop functioning
blood vessels [73,88]. These cardiovascular abnormalities
likely contribute to the FAK-null embryo lethality [68,89].
Although primitive red blood cells are present in the yolk
sac, the transport of blood cells from their site of synthesis
to the embryonic vasculature does not occur because of
blood vessel developmental defects (Fig. 6). These defects
could arise by several mechanisms, including impaired
endothelial cell differentiation, abnormal localization of
precursor cells, improper cell–matrix organization, reduced
cellular proliferation, or increased cell apoptosis. Isolation
of FAK-null endothelial cells revealed that they were unable
to form tubular structures in vitro [73]. This morphogenetic
defect was not associated with either abnormal differentia-
tion or increased apoptosis. Whereas the inability of FAK-
null endothelial cells to form an organized network of patent
vascular tubes may be related to the observed motility
defects in cell culture, it is also possible that FAK may play
a role in earlier stages of vessel assembly such as endoder-
mal cell-mediated vascular induction in adjacent mesoderm
or in facilitating the signaling connections between VEGF
receptors and integrins [90].
The failure of FAK-deficient embryos to establish a
patent cardiovascular system was associated with an
unusual concentration of maternal blood sinusoids at the
anti-mesometrial pole (Fig. 6). Interestingly, a similar
embryonic lethal phenotype at E8.5 and vascular defects
were also observed in mice lacking transcription factor
JunB [91]. Lack of JunB was associated with a deregu-
lation of proliferin, matrix metalloproteinase-9 (MMP-9)
D.D. Schlaepfer et al. / BiochimicaFig. 6. FAK-null E8.5 embryos exhibit vascular defects. Left side: half of deciduu
Right side: hemorrhaging typical for FAK-null mutant embryo with an unusual cand urokinase plasminogen activator (uPA) gene expres-
sion. On the other hand, attenuation of FAK activity
results in reduced activation of c-Jun NH2-terminal kinase
(JNK) [92–95] and inhibition of MMP-9 expression [96–
98]. Given the role of JNK in promoting JunB or AP-1
transcription factor activation [99], it is tempting to
speculate about a potential role for a FAK to JNK to
AP-1 signaling pathway in regulation of vasculo- and
angiogenesis during development and possibly during the
processes of tumorigenesis.
2.6. Zebrafish FAK connections to notochord and somite
formation
During development, increased FAK protein expression
has been detected at somite boundaries in both Xenopus
[100] and mouse embryos [87]. As null mutation of fak
in mice results in the cessation of development prior to
either notochord or somite formation, it may play an
essential role in the formation of these structures [68]. In
zebrafish, two fak genes have been identified, fak1a and
fak1b, that both contain conserved kinase domains, FAT
domains, FERM domains, and tyrosine phosphorylation
sites compared to both murine and human FAK [101].
fak1b is a gene duplication of fak1a as determined by
linkage group mapping. In situ hybridization studies of
zebrafish embryos revealed differential expression patterns
of fak1a and fak1b during development [101]. At the
shield stage, fak1b and paxillin are ubiquitously through-
out the embryo. During somitogenesis, both fak1a and
fak1b were highly expressed in the axial and head
regions. However, in a pattern distinct from fak1b, fak1a
was enriched in the notochord and segmentally expressed
in the newly forming somites [101].
Previous antibody-mediated staining studies showed
that during zebrafish somitogenesis, FAK expression is
concentrated at the basal region of epithelial cells at the
intersomitic boundary, suggesting a role for FAK in the
formation and/or stabilization of somite borders [102]. The
initiation of somite formation coincides with the accumu-m retaining healthy wild-type embryo (arrow) with normal vascular plexus.
oncentration of maternal blood sinusoids at the anti-mesometrial pole.
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FN at nascent somite borders [101]. These observations
support a role for FN to FAK signaling in somite forma-
tion. In the notochord, paxillin and phosphorylated FAK
accumulate in the circumferential rings where the noto-
chord cells contact laminin in the perichordal sheath.
Taken together, these studies support a role for integrin-
based cell adhesion and FAK activation during morpho-
genesis of the early zebrafish embryo.
2.7. FAK-integrin linkages in Drosophila
Cloning efforts by three different groups have isolated
a single gene in Drosophila that encodes a f 140 kDa
protein related to vertebrate f 120 kDa FAK [103–105].
As this gene maps to band 56 on the right arm of
chromosome 2, it has been named DFak56. DFak56 is
33% identical to vertebrate FAK, with the highest degree
of homology in domains critical for FAK function,
including the kinase domain, tyrosine phosphorylation
sites, protein interaction sites, and the FAT motif. DFak56
also contains a 104 amino acid insert of unknown
function on the C-terminal side of the FAT motif. Plating
primary Drosophila embryo cells onto matrix components
tiggrin or laminin stimulated DFak56 tyrosine phosphor-
ylation, however, the time course of Dfak56 activation
was much slower than integrin-stimulated vertebrate FAK
phosphorylation [104]. Nevertheless, highest levels of
Dfak56 mRNA and protein were localized to the central
nervous system and the muscle-epidermis attachment sites
in the embryo, the latter being the localization of posi-
tion-specific integrins [103].
In addition to integrin-stimulated tyrosine phosphory-
lation of DFak56, overexpression of DFak56 in the wing
imaginal disc resulted in wing blistering in adults, a
phenotype also observed with position-specific integrin
overexpression [104]. Endogenous DFak56 is also abun-
dant in the border cells of developing egg chambers
before the onset of, and during, their migration [105].
These border cells in the Drosophila ovary undergo a
partial epithelial to mesenchymal transition and invade
the neighboring cluster of germline cells, migrating to the
oocyte border. Recent findings have demonstrated that the
conversion of border cells from a stationary group of
epithelial cells to invasive cells required the integration of
multiple transcriptional regulatory pathways that act to
modulate the expression of proteins involved in cell
motility such as cadherin and FAK [106]. To this end,
the accumulation of elevated FAK protein levels also has
been associated with apical cell motility during Drosoph-
ila ovarian morphogenesis stimulated by a DWnt4 and
protein kinase C signaling pathway [107]. Whereas it was
not determined whether DWnt4-regulated changes in FAK
expression were transcriptionally mediated, the studies to
date in Drosophila support a role for FAK in the control
of integrin signaling and cell motility.3. Analyses of FAK function in cell culture
3.1. FAK connections to focal contact formation
One common aspect to the developmental studies
described above is that the biological role of FAK is
linked to the integrin regulation of focal contact forma-
tion and/or turnover during cell movement. Many cell-
based biochemical analyses have been focused on eluci-
dating how focal contact regulation is mediated and how
FAK may be functioning to regulate these events. To this
end, studies from many labs have observed correlations
between FAK activation, paxillin tyrosine phosphoryla-
tion, and the subsequent formation of actin stress fibers
and focal contact sites [6,8]. These events are often
connected to Rho-family GTPase activation that act as
switches existing in either an inactive GDP-bound or an
active GTP-bound form. Guanine nucleotide exchange
factors (GEFs) stimulate the GDP to GTP exchange
reaction to facilitate an active Rho-GTPase conformation.
FAK can promote sustained Rho activity after thrombin
stimulation of cells in part by enhancing the tyrosine
phosphorylation of PDZ-RhoGEF or leukemia-associated
RhoGEF [108]. Whereas it is unclear whether FAK binds
directly to either of these GEFs, two hybrid and co-
immunoprecipitation analyses showed that FAK bound
directly to p190RhoGEF via interactions of the FAK
FAT domain and the coiled-coil domain of p190RhoGEF
[109]. Importantly, FAK promoted p190RhoGEF tyrosine
phosphorylation and enhanced p190RhoGEF-mediated ac-
tivation of RhoA after integrin or growth factor stimula-
tion of Neuro2A cells. In fibroblasts, p190RhoGEF
overexpression stimulates actin stress fiber and focal
contact formation [110]. Therefore, the association and
phosphorylation of RhoGEFs by FAK is a direct route to
RhoA activation (Fig. 7).
3.2. FAK connects to GAPs as well as GEFs
In an opposite manner to GEFs, GTPase-activating
proteins (GAPs) promote the hydrolysis of GTP to GDP
to facilitate an inactive Rho-GTPase conformation. ASAP1,
a GAP for the Arf-family of GTPases, binds to the FAK C-
terminal domain through an SH3-mediated interaction.
ASAP1 overexpression in cells inhibited either growth
factor [111] or integrin-stimulated [112] cell spreading and
this effect was dependent on both ASAP1 GAP activity and
SH3 domain function. Because cell spreading requires the
formation of new focal contacts, ASAP1 GAP activity is
implicated in the regulation of focal adhesion dynamics.
Interestingly, the ASAP1 SH3 domain also binds to the
FAK-related proline-rich tyrosine kinase 2 (Pyk2) PTK and
Pyk2-mediated tyrosine phosphorylation of ASAP1 was
associated with the inhibition of ASAP1 GAP-activity
[113]. Therefore, the inhibition of GAP activity can poten-
tially lead to increased levels of Rho-family GTPases in the
Fig. 7. Model summarizing the FAK-associated signaling complexes leading to focal contact formation. Actin stress fiber assembly and cell contraction are
associated with the formation of focal contact sites and increased Rho-GTP levels. Rho-GTPases indirectly regulate myosin light chain (MLC) phosphorylation
by activating MLC kinase (MLCK) and inhibiting the regulatory MLC phosphatase. FAK-mediated increases in Rho-GTP levels can occur through multiple
mechanisms. An ERK2-dependent process is regulated by the FAK–Src signaling through multiple pathways including Grb2 binding to FAK Tyr-925,
formation of Shc–Grb2 complexes, or through the PAK1 phosphorylation of MEK1 at Ser-298. ERK2-independent signaling pathways leading from FAK to
Rho-GTPase activation include the direct binding of Rho-GDP–GTP exchange factors, p190RhoGEF and Trio to FAK. A direct role for FAK in promoting
talin binding to integrins and thus in focal contact formation is through the phosphorylation and activation of the PIPKIg.
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phosphorylate ASAP1 [113], this potential Pyk2-specific
connection may contribute in part to the aberrant regulation
of focal contact structures in FAK-null cells (see below). As
FAK also binds to Graf, a protein with GAP activity for
RhoA and Cdc42 [6], these combined studies have linked
FAK to the multi-faceted regulation of Rho-family GTPase
activity through direct binding to various GAPs or GEFs in
cells (Fig. 7).
3.3. FAK activity modulates focal contact formation
One other novel connection of FAK to focal contact
formation involves the phosphorylation of the type I phos-
phatidylinositol phosphate kinase isoform-g (PIPKIg) [114].
Recent studies have elucidated that phosphatidylinositol-
4,5-bisphosphate (PI(4,5)P2) plays a key role in the nucle-
ation of scaffolding proteins and in focal contact assembly
in part by binding to the actin- and integrin-associated
proteins vinculin and talin [115]. PIPKIg phosphorylates
PtdIns(4)-phosphate on the D5 position of the inositol ring
to make PI(4,5)P2 and PIPKIg is activated in part by
binding to talin [116]. As the talin FERM domain binds to
the integrin cytoplasmic tail, a link between integrins andthe actin cytoskeleton is established [117]. Remarkably,
studies showed that FAK activity was required for full
PIPKIg activity, that FAK promoted PIPKIg tyrosine phos-
phorylation, and that these events enhanced PIPKIg binding
to talin [114]. In carcinoma cells, FAK-mediated signaling
was required for an epithelial to mesenchymal transition, as
an activated Src-FAK complex promoted the dissolution of
cadherin-based contacts and the formation of h1-integrin
focal contact sites [118].
3.4. FAK-null fibroblasts as a model system to elucidate
FAK function
Although FAK is linked to the formation of focal con-
tacts as discussed above, FAK-null fibroblasts exhibit mo-
tility defects due in part to elevated Rho activity, increased
focal contact formation, and the inability to remodel contact
sites in response to various motility stimuli [15,89,119,120].
This cellular response is unique to the loss of FAK as null
mutations in other FAK- and focal contact-associated pro-
teins such as paxillin [27], p130Cas [121], or Src-family
PTKs [122] do not yield a similar morphological phenotype
as FAK-null cells. One possible contributing factor to this
seemingly incongruous FAK-null phenotype may be the
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that is not normally expressed at high levels in fibroblasts
[15] (Fig. 8). Nevertheless, targeting a Pyk2 chimeric
protein to focal contact sites by fusion to the FAK C-
terminal domain [123] or stable FAK re-expression rescues
both the morphological and signaling defects of FAK-null
cells [35,124,125]. Additionally, studies using antisense to
reduce FAK expression in carcinoma cells also found that
FAK was a required component for optimal cell motility
[97]. As migration is a dynamic process, it is probable that
an important regulatory protein such as FAK may exhibit
differential signaling leading to either the formation or
turnover of focal contacts, the output of which is dependent
upon the make-up of proteins associated with FAK at a
particular time and location within cells.
3.5. Analyses of FAK mutants expressed in FAK-null cells
As FAK is expressed in many cell types, FAK-null
fibroblasts provide a unique model system in which to
evaluate wild-type and various FAK mutants in gain-of-
function studies. Time-lapse video microscopy of reconsti-
tuted fibroblasts showed that FAK promotes increased cell
migration speed and directional persistence of cell move-Fig. 8. FN-stimulated signaling in FAK-null fibroblasts. Expression of the FAK-re
with Src-family PTKs after FN-stimulation. However, Pyk2 is peri-nuclear distribu
null cells. FN-stimulated signaling through Ras to ERK2 is decreased in amplit
signaling pathways to JNK are not readily activated, whereas corresponding eleva
formed exacerbated FAK-null cell motility defects. The inability to effectively rem
FAK-null migration defects. Targeting chimeric Pyk2 proteins to focal contacts in
ERK2 and JNK, elevated cell motility, and can reverse the FN matrix organizatioment [75]. Expression of a Phe-397 FAK mutant showed
similar defects as FAK-null cells and in endothelial cells
expressing a green flourescent protein (GFP) fusion with
FAK (GFP-FAK), the polarized increase in FAK Tyr-397
phosphorylation selectively occurred at the leading edge of
motile cells [126]. These results reinforce the fact that
spatial regulation plays an important role in FAK signaling.
As Src catalytic activity is also needed for cell spreading and
migration [127], the inability of a Phe-397 FAK mutant to
rescue either integrin or growth factor-stimulated FAK-null
motility defects is consistent with the hypothesis that the
formation of a Src-family PTK-FAK complex is the first of
several events needed to promote focal contact turnover and
cell motility [15,35]. The formation of a Src-FAK complex
also occurs after G protein-linked FAK activation and can be
dependent upon either FAK autophosphorylation of Tyr-397
[128] or Src-mediated transphosphorylation of FAK at Tyr-
397 [129].
The goal of comparative FAK reconstitution studies is to
connect FAK phosphorylation sites, kinase activity, or
protein binding domains with the rescue of FAK-null cell
motility defects. The answers obtained so far show that the
mechanistic role of FAK is highly context-dependent. For
integrin-stimulated cell motility assays, the FAK Tyr-397lated PTK, Pyk2, is elevated in FAK-null cells and Pyk2 forms a complex
ted and does not strongly localize to integrin-enriched focal contacts in FAK-
ude and duration in FAK-null compared to wild-type cells. FN-stimulated
ted levels of Rho-GTPase activity and increased numbers of focal contacts
odel focal contacts in response to motility-promoting stimuli contributes to
FAK-null cells can promote focal contact remodeling, increased signaling to
nal defects also observed in cultures of FAK-null cells.
D.D. Schlaepfer et al. / Biochimica et Biophysica Acta 1692 (2004) 77–102 89site, kinase activity, and the C-terminal proline-rich domains
were required [15]. For growth factor-stimulated cell motil-
ity assays, expression of kinase-inactive FAK mutant func-
tioned equally to wild-type FAK, whereas the Phe-397 FAK
mutant was inactive [35]. This differential role of FAK
kinase activity needed for integrin but not growth factor-
stimulated cell motility events is likely due to the fact that
integrins do not possess intrinsic catalytic activity, whereas
many growth factor receptors can trans-phosphorylate FAK
at Tyr-397. Additionally, since expression of a FAK mutant
lacking C-terminal SH3 binding sites for p130Cas, Graf,
and ASAP1 functions to promote growth factor-stimulated
FAK-null cell motility [35], but not FN-stimulated FAK-null
cell motility [125], suggests that the downstream targets or
mechanisms through which FAK functions to promote cell
motility may differ depending on the particular migration
stimulus.
3.6. FAK-null cell signaling defects
Some of the major signaling defects associated with
FAK-null cells are the reduction in the extent and duration
of integrin and growth factor-stimulated ERK2 as well as
JNK activation (Fig. 8). A number of labs have found that
FAK-mediated signaling to either ERK2 or to JNK does not
follow a single linear pathway [8,15]. To this end, novel
signaling connections continue to be uncovered such as
FAK-enhanced p21-activated kinase (PAK) phosphorylation
of MAPK kinase 1 (MEK) at Ser-298 can facilitate ERK2
activation [130] and direct FAK FERM domain binding and
phosphorylation of the JSAP1 scaffolding protein may
facilitate JNK activation [131]. Despite findings of JNK-
mediated phosphorylation of FAK-associated proteins such
as paxillin, and the overexpression of a paxillin phosphor-
ylation site mutant blocking cell motility [132], singular
activation of either ERK2 or JNK pathways is not sufficient
to rescue FAK-null cell motility defects [123]. This may be
due to the fact that the activation of signaling targets such as
nuclear factor nB are also impaired in FAK-null cells [133].
As FAK signaling can induce the expression of Prx1 [134]
and KLF8 [29] transcription factors as well as other effector
proteins involved in promoting focal contact remodeling
[97,135], it is likely that the regulation of multiple targets
are involved in mediating FAK-stimulated cell motility
events.
3.7. FAK linkages promoting focal contact turnover
In addition to functioning as an integrator and amplifier
of signaling to ERK2 and JNK, FAK or Pyk2-FAK chimeras
need to be appropriately localized to focal contact sites in
order to reverse the motility defects of FAK-null cells [123].
This raises the possibility that there may be critical target(s)
or substrate(s) of FAK localized within focal contact sites
that are not being appropriately regulated in the absence of
FAK expression. In addition to the contributions of FAKsignaling to JNK with respect to gene expression changes,
FAK functions to promote the transient recruitment of JNK
to focal contact sites after integrin stimulation of cells [94].
Activated ERK2 is also transiently recruited to focal contact
sites [136]. Interestingly, MEK kinase 1 (MEKK1) has been
shown to associate with FAK [137] and MEKK1 can
regulate both the ERK and JNK pathways. Recent studies
showed that MEKK1 regulation of ERK activity was needed
for the activation of the calpain protease and for the
cleavage of focal contact-associated talin [138]. As cal-
pain-null cells exhibit the formation of large focal contacts
and motility defects, it has been proposed that calpain
protease activity is needed to promote focal contact turnover
[139].
The role of FAK as an activatable scaffold protein
promoting focal contact turnover is supported by studies
showing that the transient expression of FAK in FAK-null
cells promoted the localization of calpain 2 and activated
ERK to focal contact sites and that FAK expression was
required for maximal calpain activity [140]. FAK formed a
complex with calpain 2, ERK2, and activated viral Src (v-
Src) and this was associated with focal contact turnover
during cell migration and v-Src-mediated cell transforma-
tion [140]. As FAK activation has been associated with
intracellular calcium spike-mediated disassembly of focal
contacts [141] and as calpain 2 is a calcium-activated
protease, the FAK-mediated targeting of an activated
calpain complex and the cleavage of integrin- and actin-
associated proteins such as talin directly connects FAK
signaling to focal contact turnover (Fig. 9). Whereas these
connections are appealing in simplicity, there are also
likely other targets downstream of the FAK–Src complex
that also may contribute to focal contact turnover [24,142].
To this end, FAK can form a complex with G protein
coupled receptor (GRK)-interacting targets (GIT) that pos-
sess Arf-GAP activity, binding sites for paxillin, and which
localizes to focal contacts [143]. Comparisons of GIT1
localization in FAK-null, FAK-reconstituted (DA2) and
wild-type fibroblasts shows that FAK expression is needed
for the recruitment of GIT1 to focal contacts (Fig. 10). The
FAK–Src complex can promote GIT1 tyrosine phosphor-
ylation and both FAK and GIT1 act to facilitate focal
contact turnover independent of actin-myosin contractility
events [142,143]. Whereas it has been proposed that the
interaction of paxillin with FAK or GIT1 provides a
mechanism for disengagement of paxillin from, and con-
sequent disassembly of focal contacts, this hypothesis
remains to be proven.
3.8. FAK connections to cell invasion go beyond the control
of cell motility
Tumor cell invasion through matrix and tissue barriers
requires the combined effects of increased cell motility and
regulated proteolytic degradation of the matrix. Though FAK
expression is elevated in invasive humans cancers [12–
Fig. 9. Model summarizing the FAK-associated signaling complexes leading to focal contact turnover. The inhibition of Rho-GTPase activity is associated with
the re-arrangement of actin and the disassembly of focal contact sites. Binding of SH3 domain-containing GAP proteins such as Graf or ASAP1 connect FAK
with the regulation of Rho-GTPases and Arf GTPases, respectively. FAK–Src signaling regulating the tyrosine phosphorylation of p190RhoGAP is another
pathway leading to the inhibition of Rho-GTPase activity. Focal contact turnover can also be facilitated by selective proteolysis of adhesion-associated proteins
such as talin. FAK also functions as a scaffolding protein in binding calpain, MEKK1, and ERK2 to target calpain proteolytic activity to focal contact sites. For
both assembly and disassembly mechanisms, inhibition of paxillin binding to FAK decreases FAK association with integrins and reduces FAK function in
modulating these signaling pathways.
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cells have relied upon measurements of cell motility in two
dimensions rather than cell invasion in three dimensions
[145]. Albeit that cell motility is an integral part of cell
invasion, v-Src-mediated cell transformation studies re-Fig. 10. FAK expression facilitates GIT1 recruitment to focal contacts. Indirec
Transduction Labs) was performed on paraformaldehyde-fixed wild-type (FAK+/+
plated onto FN-coated slides in the presence of serum. Arrowheads show preferen
DA2 cells. GIT1 shows a strong perinuclear and weak focal contact staining pattvealed that naturally occurring v-Src SH3 domain mutations
enhanced v-Src binding to and phosphorylation of FAK
[146]. This tight v-Src association with FAK resulted in
increased cell invasion through a reconstituted basement
membrane barrier as determined by v-Src expression int immunofluorescent staining using a monoclonal antibody to GIT1 (BD
), FAK-null (FAK / ), or FAK reconstituted (DA2) fibroblasts that were
tial GIT1 staining at cell periphery focal contact structures in FAK+/+ and
ern in FAK-null cells.
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increased cell invasion activity was independent of changes
in either cell motility or cell transformation by v-Src.
However, the invasive phenotype was associated with the
accumulation of v-Src-FAK signaling complexes within
invadopodia, cell extensions enriched in integrins and matrix
metalloproteinases (MMPs) [147]. In related studies, FAK
overexpression in squamous cell carcinomas and lung
adenocarcinomas has been shown to promote three-dimen-
sional cell invasion activity [97,148].
Three different laboratories have expressed various v-Src
isoforms in FAK-null cells to test the role of FAK in Src-
mediated cell transformation [98,149,150]. v-Src expression
led to the FAK-independent tyrosine phosphorylation of
paxillin as well as increased Pyk2 tyrosine phosphorylation
in FAK-null cells. Whereas Pyk2 activation is not sufficient
to rescue the FAK-null motility defects [151], v-Src trans-
formation reversed the rounded cell morphology and motil-
ity defects of FAK-null cells [98,150]. As FAK-null cells
exhibit elevated levels of Rho activity and inhibition of this
pathway can partially reverse FAK-null cell motility defects
[119,120], a common target for both v-Src and FAK activity
is the tyrosine phosphorylation of p190RhoGAP [98].
Although it was not proven that v-Src-mediated p190Rho-
GAP phosphorylation was the link to the promotion of
FAK-null cell motility, it is an event associated with
decreased Rho activity and increased focal contact turnover
in cells [152,153] (Fig. 9). As the v-Src studies also revealedFig. 11. FAK–Src-p130Cas signaling promoting an invasive cell phenotype. v-Sr
contact remodeling and motility defects, but FAK re-expression was required to pro
an activated Src complex to focal contacts and invadopodia cell projections. Th
signaling complex that also contains the Dock180 GEF for the small GTPase, Ra
strong JNK activation and the phosphorylation of transcription factors known to
elevated MMP secretion localized to invadopodia may act to promote targeted mathat FAK expression was not essential for the promotion of
anchorage-independent cell growth [149,150], these studies
support the importance of Src activation in overcoming
FAK-null cell motility defects.
In addition to pushing cells to anchorage-independent
cell growth, v-Src is a potent oncogene that promotes cell
invasion in vitro and experimental metastasis in vivo [154].
However, v-Src-transformed FAK-null cells did not possess
an invasive cell phenotype compared to v-Src-FAK-contain-
ing cells [98]. This result suggests that the role of FAK in
promoting v-Src-stimulated cell invasion may be distinct
from the signaling connections needed to reverse the integ-
rin-stimulated FAK-null cell motility defects. This conclu-
sion is supported by results showing that dominant-negative
inhibition of FAK activity blocked v-Src-stimulated cell
invasion and experimental metastases in nude mice without
effects on in vitro cell motility [155]. Inhibition of FAK
activity led to decreased MMP gene transcription and this
was associated with the selective loss of an invasive cell
phenotype. Inhibition of MMP expression has also been
observed after FAK antisense treatment of carcinoma cells
[135,156]. These studies support the conclusion that FAK
may function to promote cell motility and cell invasion
through distinct mechanisms. For cell motility, FAK signal-
ing controls the formation and turnover of focal contact sites
and for cell invasion, FAK signaling alters MMP expression
and promotes the generation of an invasive cell phenotype
(Fig. 11).c transformation of FAK-null cells was a sufficient stimulus to rescue focal
mote three-dimensional invasive motility. FAK facilitates the localization of
e adaptor proteins p130Cas and Crk can be found within this FAK–Src
c. Combined integrin and serum-enhanced FAK signaling to Rac promotes
regulate MMP expression. A FAK to Rac signaling pathway leading to
trix degradation leading to an invasive and metastatic tumor cell phenotype.
D.D. Schlaepfer et al. / Biochimica et Biophysica Acta 1692 (2004) 77–10292FAK-mediated cell invasion was associated with the
accumulation of FAK in invadopodia and in two dimen-
sions, serum stimulated the transient re-localization of FAK
from a cytoplasmic pool to lamellipodia and membrane
ruffles [98]. No detectable loss of FAK at focal contacts was
observed during the transient accumulation of FAK atlamellipodia, indicating that FAK may form distinct signal-
ing complexes depending upon its localization to either
focal contacts or lamellipodia (Fig. 12). As activated FAK
(phosphorylated at Tyr-397, 576, and 577) is selectively
enriched in both growing and retracting pseudopodia [157],
it is possible that tumor cell invadopodia may contain many
of the same signaling constituents localized to lamellipodia
or pseudopodia. In v-Src transformed FAK-null reconstitu-
tion studies, FAK kinase activity, Tyr-397 phosphorylation,
and the integrity of the C-terminal domain proline-rich SH3
binding sites on FAK were all required for the generation of
an invasive cell phenotype [98].
FAK expression in v-Src-transformed FAK-null cells
promoted the formation of a v-Src-p130Cas-Crk-Dock180
signaling complex, led to the selective elevation of Rac
GTPase and JNK activation, and resulted in increased
MMP2 activity and MMP9 expression (Fig. 11). Interesting-
ly, whereas FAK, p130Cas, Crk and Rac are commonly
involved in pseudopodia growth and invasion, the uncou-
pling of Crk from p130Cas during pseudopodium retraction
was independent of changes in FAK activity [157], and Crk
binding to p130Cas was not the switch that regulated FAK-
mediated cell invasion [98]. These differences are likely due
to the differential role of various p130Cas domains in the
regulation of cell migration, cytoskeletal rearrangements, and
in Src-mediated cell transformation events [121,158]. Nev-
ertheless, since Src activation contributes to the metastatic
spread of carcinoma cells [159] and FAK activation is a
common component promoting h6 integrin-mediated cancer
progression [160] or h4-integrin-mediated metastatic growth
[161], it is likely that FAK–Src signaling may synchronize
MMP-mediated matrix proteolysis and cell motility, thereby
facilitating an invasive cell phenotype. Further, as irradiation-
induced glioma cell invasion is associated with increased
FAK activation, the prevention of this invasive phenotype by
treatment with subtoxic levels of temozolomide is associated
with FAK cleavage and destruction [162].4. FAK-related non-kinase (FRNK)
In many studies, exogenous expression of FRNK has been
utilized as a dominant-negative mutant to inhibit FAK sig-
naling. FRNK does not possess catalytic activity and com-
prises the C-terminal region of FAK with proline-rich motifs
for SH3 binding proteins followed by the FAT domain (seeFig. 12. FAK localizes transiently to lamellipodia of migrating cells. Time-
lapse confocal microscopy image series of GFP-FAK expression within v-
Src-transformed FAK-null cells. Arrows denote the transient accumulation of
GFP-FAK at leading membrane lamellipodial ruffles in a migrating cell. This
FAK accumulation at ruffles was not accompanied by a loss of FAK already
integrated into focal contacts. As lamellipodial-associated GFP-FAK
dissipated, strong GFP-FAK association was detected with small transient
focal contacts at the cell periphery behind the leading edge of the membrane
ruffle. This focal contact-associated GFP-FAK signal ultimately coalesced
into focal adhesions, moved toward the cell center, and then dissipated.
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activity, its expression promotes FAK tyrosine dephosphor-
ylation. Models have been proposed to explain the mecha-
nism of FRNK inhibition of FAK either by the competitive
displacement of FAK from integrin-containing focal contacts
or titration of critical signaling partners away from FAK. A
displacement inhibitory model is favored as the integrity of
the FAT domain within FRNK is required for its inhibitory
activity toward FAK. To this end, the expression of leucine to
serine mutation within the FAT domain of FRNK (FRNK S-
1034) has been used as a control in studies using FRNK
overexpression to inhibit FAK [125,163]. Although FRNKS-
1034 still can bind targets such as p130Cas, it exhibits a
cytoplasmic localization and does not lead to FAK dephos-
phorylation in cells compared to FRNK.
4.1. Is FRNK an endogenous regulator of FAK activity in
mammalian cells?
In chicken embryo cells, the major FAK-related poly-A
RNA transcript is f 2.5 kb encoding the open reading
frame of the FAK C-terminal domain [8]. Interestingly, a
less abundant transcript of 4.5 kb encodes full-length FAK
[8]. The 2.5 kb chicken FRNK mRNA contains a leader
sequence that is encoded by a novel exon that resides within
an intron of the full-length fak gene [164]. In cell culture-
based assays, this putative exon region exhibits promoter
activity in a cell type-specific manner. However, this pro-
moter region does not contain a TATA box and the regula-
tion of FRNK-specific mRNA transcription remains
undetermined. In chicken tissues, expression of FAK is
ubiquitous, whereas FRNK expression is restricted to lung,
intestines, and muscle [164]. Surprisingly, in many mam-
malian cell lines, FRNK expression is minimal or not
readily detectable. As FAK can be proteolytically degraded
by calpain or caspase activity leading to the generation of
FRNK-like protein products [8], there remains some con-
cern about the general prevalence of FRNK acting as an
endogenous regulator of FAK activity.
However, it is possible that the regulation of FRNK
expression may be context specific. In 3-week-old rat tissues,
a f 2.2 kb presumptive FRNKRNA product was detected in
lung, thoracic artery, and in primary vascular smooth muscle
cells (VSMC) [19]. RNase protection was used to support the
existence of this FRNK-specific mRNA containing a novel 5V
region. Expression of a FRNK-specific mRNA in tissues was
correlated with the detection of f 43 kDa FRNK byWestern
blotting [19]. Genomic sequencing analyses of murine FAK
confirm the existence of a cryptic exon and intron splice site
at residue 118290 of chromosome 15 (NCBI, Build 32) and
this also matches the organization of the chicken fak gene
within the putative FRNK promoter region.
During mouse development, FRNK protein expression
was detected in smooth muscle tissues and FRNK expres-
sion was up-regulated 2 weeks after induced vascular injury
[19]. As FRNK protein production can be stimulated byplating VSMCs onto a perlecan-enriched basement mem-
brane without detectable loss of FAK expression [20], it
may be the changing composition of matrix proteins within
the site of vascular injury or the beginning stages of
restinosis that may modulate and promote FRNK expression
in vivo. Notably, perlecan-stimulated FRNK expression was
correlated with decreased FAK tyrosine phosphorylation
and the inhibition of cell growth [20]. This could be
reversed by overexpression of wild-type but not FAK-
mutated at Tyr-397, thus supporting a competitive model
of inhibition between FRNK and FAK. As adenoviral-
mediated overexpression of FRNK in primary VSMCs also
resulted in the inhibition of growth factor-stimulated cell
proliferation, it has been hypothesized that endogenous
FRNK may act to limit VSMC growth [19]. However, other
studies have found that stable FRNK expression did not
significantly inhibit VSMC cell growth, but instead, blocked
growth factor-stimulated cell motility responses [163].
Interestingly, FRNK-mediated phenotypes can range
from the inhibition of cell growth to more subtle migration
defects without affecting cell survival or proliferation. It is
possible that these seemingly contradictory effects may be
due to cell background differences, the level of remaining
FAK tyrosine phosphorylation in the presence of FRNK, or
the ratio of FRNK to FAK expression within cells. As
elevated protease activity in tissues can create FRNK-like
peptides by cleavage of FAK, future studies using a com-
bination of reverse-transcriptase PCR analyses and FRNK
protein detection may be the best strategy to definitively
characterize the regulatory factors controlling endogenous
FRNK production.
4.2. FRNK expression can promote apoptosis
As FAK has been shown to promote cell survival signals
downstream of integrins [94,165], after UV irradiation
[166,167], after staurosporin [168] or hydrogen peroxide
treatment [169], it is not surprising that FRNK expression
can result in the inhibition of cell proliferation, loss of cell
adhesion, and activation of caspase-mediated cell death
[170]. In BT474 breast carcinoma cells, FRNK expression
caused a lethal phenotype in part through the activation of
caspases-3 and -8, resulting in cleavage of poly (ADP-
ribose) polymerase and Akt [171]. In these BT474 cells,
apoptosis could be rescued by overexpression of an inactive
form of the Fas-associated death domain or by activation of
the EGF receptor implicating the interplay of death receptors
and growth factor signaling in FRNK-mediated cell death
[171].
Integrin to FAK signaling is also associated with the
cardiac myocyte hypertrophy, an increase in protein synthe-
sis and cell size without accompanying cell division [172–
174]. FAK activation in myocytes can occur after stretch
[175], pressure overload [176], and neurohormonal stimuli
[177–179]. FAK activation is associated with cytoskeletal
association, FAK Tyr-397 and Tyr-925 phosphorylation,
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proteins p130Cas, Shc, and Grb2 to FAK, downstream
activation of ERK2, and corresponding changes in gene
expression [174,179–181]. FRNK expression in cardio-
myocytes has been shown to block FAK tyrosine phosphor-
ylation and ERK2 activation [177,179], inhibit protein
synthesis [177,178], and block hypertrophy-associated gene
expression [179,180]. Upon extreme overexpression, ade-
noviral-mediated FRNK promoted the loss of FAK and
paxillin from focal adhesions followed by cell detachment,
and apoptosis [182].
Resultant cell death after FRNK expression in carcinoma
cells and cardiomyocytes was associated with high levels of
overexpression. Notably, it is the C-terminal FAT domain of
FRNK that is the most potent inducer of cell death when
expressed apart from FRNK [94]. To this end, high levels of
FRNK expression in rabbit synovial fibroblasts did not
promote apoptosis due in part to pro-survival signals medi-
ated by p130Cas binding to proline-rich sites in FRNK that
are not present within the FAT domain [94]. Overall, it is
also possible that cell type differences may play a role in the
resistance to FRNK-mediated cell apoptosis [183,184]. Fi-
nally, stable expression of FRNK has been achieved in a
variety of cell types without effects on cell growth [155,163].
In these FRNK-expressing cells, the limited inhibition of
FAK signaling has provided useful insights on the molec-
ular mechanisms of FAK-associated signals controlling cell
motility.
4.3. FRNK-mediated inhibition of cell migration and
invasion
Studies with FAK have shown that it functions to inte-
grate growth factor- and integrin-stimulated signals promot-
ing cell migration. The selective blockage of the integrin to
FAK activation pathway via FRNK expression has provided
important clues as to the role of FAK in promoting cell
motility. PDGF-BB stimulated VSMC motility can be
blocked by either stable [163], or transient [19] expression
of FRNK. In these experiments, FRNK expression inhibited
extent and duration of ERK2 activation stimulated by low
motility-promoting concentrations PDGF-BB [163]. In other
studies with VSMCs, FRNK expression inhibited the tyro-
sine phosphorylation of p130Cas, phosphorylation of FAK at
Tyr-397, Tyr-576, Tyr-861, and attenuated PDGF-BB sig-
naling to Rac and JNK [92]. In carcinoma cells and fibro-
blasts, FRNK expression also blocked EGF-stimulated
chemotaxis, FAK Tyr-397 phosphorylation, FAK association
with the EGF receptor, and EGF-stimulated ERK2 and JNK
activation [35,97].
Since it is the FAK N-terminal FERM domain which
facilitates the association with an activated EGF receptor
complex [35], it is interesting to speculate as to how FRNK
may act to inhibit a FAK-EGF receptor association, espe-
cially since FRNK is proposed to block FAK function by
excluding FAK from focal contact sites. As focal adhesion-excluded FAK does not interact with the EGF receptor
complex in the presence of FRNK, FAK association with
growth factor receptors may be either initiated at focal
contact sites or may require conformational FAK activation
via an integrin linkage. Alternatively, FRNK may have
secondary effects apart from competing with FAK at focal
adhesions, such as the inhibition of a signaling pathway
required as a co-stimulus for the formation of a FAK–EGF
receptor complex.
As discussed in Section 3.5, the formation of an
activated FAK–Src complex is the first of several sig-
naling events needed to promote focal contact turnover
and to initiate cell motility. Transient FRNK expression
in various prostate carcinoma cell lines acts to block cell
motility as does treatment with the pharmacological PP2
inhibitor of Src-family PTKs; further supporting the role
of FAK–Src signaling in prostate carcinoma cell migra-
tion [145,185]. However, stable FRNK expression in v-
Src-transformed NIH3T3 fibroblasts did not inhibit che-
motaxis or haptotaxis when compared to FRNK S-1034
expressing cells [155]. This may be partly due to the
ability of v-Src to associate and phosphorylate FAK in an
adhesion-independent manner [146] or this situation may
reflect the partial inhibition of FAK signaling by moder-
ate levels of stable FRNK expression as opposed to
transient high levels of FRNK used in other studies.
Nevertheless, even though stable FRNK expression in
v-Src NIH3T3 fibroblasts did not affect cell motility,
FRNK blocked cell invasion through a reconstituted
basement membrane in vitro and experimental metastasis
formation in vivo [155]. These results were the first to
distinguish potential separate roles for FAK signaling in
promoting cell motility or cell invasion.
It was determined that FRNK expression acted to limit the
strength of v-Src–FAK signaling complex, leading to re-
duced FAK phosphorylation at C-terminal sites such as Tyr-
861 and Tyr-925, and FRNK acted to limit the tyrosine
phosphorylation of FAK-associated proteins such as
p130Cas [155]. Notably, FAK Tyr-397 phosphorylation
and v-Src-associated kinase activity were unchanged when
comparing FRNK or FRNK S-1034-expressing cells. This
provides one explanation as to why FRNK did not affect the
motility of v-Src-transformed cells. Although both JNK and
ERK2 activities were reduced in FRNK-expressing v-Src-
transformed NIH3T3 cells, the use of pharmacological
inhibitors showed that the selective blockage of JNK acti-
vation was associated with the invasion defect [155]. Eval-
uation of protease secretion revealed that the FAK–Src–
JNK signaling pathway could act to modulate the expression
and secretion of MMPs [155] and the results using FRNK to
inhibit FAK were very similar to the results obtained after v-
Src transformation of FAK-null and FAK-reconstituted cells
[98] (Fig. 11). Since JNK phosphorylation of transcription
factors can affect gene transcription events [186], and many
proteases contain JNK-responsive AP1 sites within the
promoter regions [187], it has been proposed that FAK
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invasive cell phenotype.
4.4. FRNK blockage of FAK signaling within endothelial
cells
Angiogenesis requires endothelial cell proliferation,
transmigration, and coalescence into tubes prior to secretion
of the surrounding basal lamina. VEGF stimulation of
endothelial cells may be sufficient to promote all of the
above responses. VEGF has been shown to induce FAK
translocation to focal contacts, to increase FAK phosphor-
ylation at Tyr-397 and Tyr-861, and to promote the forma-
tion of a FAK–integrin avh5 complex in human umbilical
vein endothelial cells (HUVECs) [55,188]. This integrin–
FAK association is promoted by a VEGF-Src signaling
connection and affects endothelial cell chemotaxis and
wound healing responses. This VEGF signaling pathway
is dependent on the C-terminal region of the VEGF receptor
and can be blocked by FRNK expression [189].
FRNK expression in human brain microvascular endo-
thelial cells also resulted in the inhibition of cell migration
and capillary tube formation in collagen [190,191]. FRNK
localized to focal adhesions in these cells and blocked
VEGF-induced migration in part by blocking signals re-
quired for VEGF-stimulated focal contact formation [190].
These results using FRNK expression to inhibit FAK
activity in vascular endothelial cells, corresponds well to
the lack of developmental blood vessel morphogenesis in
the absence of FAK expression [73].
In addition to a role in promoting endothelial tubule
formation, FAK signaling has been proposed to be impor-
tant for the strengthening of endothelial cell–cell barriers
that regulate blood–tissue fluid flux [192]. Hyperosmolar
challenge of endothelial cell monolayers resulted in in-
creased actin filament density, FAK and E-cadherin locali-
zation to the cell periphery, and increased barrier
strengthening as measured by increased electrical resistance.
Expression of a dominant-negative form of Rac, blocked the
hyperosmolar change in actin, but did not affect the endo-
thelial barrier enhancement response. In contrast, expression
of FRNK blocked the accumulation of FAK and E-cadherin
at the cell periphery and blunted the increase in electrical
resistance stimulated by hyperosmolarity [192]. These stud-
ies with FRNK support a novel role for FAK to Rac
signaling in establishing the endothelial barrier strengthen-
ing response. Thus, the use of FRNK as a specific tool to
inhibit FAK activity continues to yield insights into novel
FAK signaling connections.
4.5. FRNK as a tool to evaluate FAK function in malignant
tumor progression
Elevated FAK expression, in part through gene amplifi-
cation [193], has been observed as a function of increasing
tumor malignancy. As exogenous FAK overexpression inhuman astrocytomas increased tumor growth in soft agar or
after orthotopic implantation in mice [194], potentially
through the increased signaling to ERK2/MAP kinase
[195], it has been proposed that elevated FAK expression
may provide a selective growth advantage to tumor cells
(Fig. 13). Immunohistochemical analyses have also found
that FAK expression was elevated in pre-invasive and
invasive carcinomas, suggesting that up-regulation occurs
at an early stage of tumorigenesis and may act to promote
the transition to an invasive phenotype [196]. However, in
order to study the role of FAK in malignant tumor
progression, one needs to inhibit FAK activity within
tumors and cell lines. In the absence of pharmacological
inhibitors to FAK, FRNK expression is the best available
method for the inhibition of endogenous FAK within tumor
cells.
The use of recombinant adenovirus to facilitate exoge-
nous FRNK expression in lung carcinoma cells has shown
that FRNK can block EGF-stimulated cell motility [97]. In
this study FRNK suppressed FAK signaling to both JNK
and ERK-2 pathways resulting in reduced MMP-9 secretion
[97]. The JNK pathway also has been implicated as an
important target in promoting FAK-initiated signals control-
ling tumor cell invasion [98]. However, FAK inhibition by
FRNK in many cell lines results in the combined inhibition
of both tumor cell migration and invasion in part through
effects on multiple signaling pathways and therefore the
signaling connections associated with a given phenotype are
not easily identified.
In studies where stable FRNK expression has been
achieved, variable effects on tumor growth have been
reported. In studies with v-Src transformed NIH3T3
fibroblasts, FRNK- and FRNK S-1034 expressing cells
formed subcutaneous tumors in nude mice with equal
efficiency [155]. FRNK expression did not affect cell
viability in culture and it was postulated that v-Src-
mediated activation of signaling targets such as Akt
may be related to the lack of growth inhibitory effects
of FRNK in v-Src-transformed cells [155]. Nevertheless,
FRNK expression in v-Src NIH3T3 fibroblasts resulted in
the inhibition of experimental lung metastases, reinforcing
the importance of FAK signaling in regulating tumor cell
spread to secondary organs. Although it is possible that
FRNK expression in v-Src transformed cells could reduce
cell survival within the bloodstream under anchorage-
independent conditions, FRNK-expressing v-Src NIH3T3s
exhibited equal colony growth in soft agar. By over-
expressing either wild-type or catalytically inactive
MMP2 in FRNK-expressing v-Src NIH3T3s, it was
determined that the FRNK effects on cell invasion and
experimental metastasis were associated with the reduced
production and secretion of this protease [155].
In Hep3 human carcinoma cells overexpressing the uPA
receptor (uPAR), tumorigenicity is associated with uPAR-
mediated integrin activation, FAK tyrosine phosphorylation
and Src recruitment, and downstream ERK2 activation
Fig. 13. Proposed roles of FAK in malignant tumor progression. Clinical correlates have found that conversion of pre-invasive solid tumors to an invasive state
is often accompanied by elevated FAK expression and tyrosine phosphorylation. The sub-population of FAK-overexpressing cells may secrete elevated levels
of MMPs, thereby breaking down basement membrane barriers facilitating both tumor spread and potentially tumor growth via the proteolytic release of
stromal-associated growth factors. In cell culture, the FAK-stimulated invasive cell phenotype is accompanied by the activation of downstream effectors such as
JNK, ERK2, Rac, MMP-2 and MMP-9. As FAK signaling promotes both increased cell motility and invasion, FAK overexpressing cells may acquire a very
aggressive phenotype. Additionally, elevated levels of FAK signaling affecting apoptosis and cell survival are likely to influence the transition to a metastatic
stage where tumor cells gain access to blood vessels and disseminate to distant sites.
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resulted in much smaller tumors compared to FRNK S-1034-
expressing cells when implanted on chicken chorioallantoic
membranes [199]. As FRNK expression did not increase
apoptosis, it was concluded that the FRNK-expressing
tumors reached a state of dormancy in vivo. This was
associated with reduced ERK2 activity and tumor dormancy
could be partially rescued by active MEK1 in the presence of
FRNK [199]. Therefore, the FAK-regulated ERK pathway
may be important in regulating the growth of tumor cells in
vivo. The above studies using FRNK provide important
information regarding the role of FAK in promoting tumor
growth and metastasis.5. Summary
FAK has been demonstrated to play important yet
differing roles in signaling pathways associated with
normal and tumor cell movement. As FAK functions as
both a scaffold and as a kinase, the future development
of pharmacological inhibitors to FAK may be used to
discriminate whether normal cell motility or malignant
cell invasion events differentially depend on FAK cata-
lytic activation. The continued characterization of FAK-interacting proteins will provide a better understanding of
the potential for multiple and novel signaling connec-
tions, yet better methods are still needed to visualize the
spatio-temporal regulation of FAK activation at focal
contacts, lamellipodia, and invadopodia. Finally, the re-
constitution and transformation of FAK-null fibroblasts
has proven to be good model system in which to define
the role of FAK in promoting focal contact turnover and
in the generation of an invasive cell phenotype. As FAK
is highly expressed and activated in many highly malig-
nant tumors, the comparative use of FAK-null cells and
the inhibition of FAK expression or activity in tumor
cells should provide important insights as to how FAK
contributes to other aspects of tumorigenesis such as
growth, survival, and angiogenesis in addition to cell
motility and invasion.Acknowledgements
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